Healthpeak Properties Inc (DOC)

Investment Committee Summary

Investment Thesis

At $18.95 (13 October 2026) Healthpeak trades on 10x guided funds from operations, close to its 52-week high, with the distribution rather than growth supplying the return. The market is pricing a stable-rate, slow-growth outpatient and laboratory landlord: mid-single-digit same-store net operating income growth, no re-rating, income as the return. The engine differs on the left tail, not the base. Variance decomposition attributes the great majority of outcome dispersion to the multiple, and the scenario set carries a heavy structural state of rate shock plus laboratory oversupply whose target sits below the 52-week low, alongside a recession state beneath spot. Probability-weighting the paths gives $20.70, with a twelve-month target of $20.66, while the triangulated fair value of $19.97 leaves a gap of +5% to spot, so the shares are fairly valued against that anchor. HOLD follows: the base case is already priced, peer forward multiples are not a usable anchor for a levered REIT carrying net debt of ~$9.5B, and the portfolio's 18% (reported GAAP, TTM to Jun 2026) operating margin is a property-level figure rather than a cushion. The single most damaging risk is a sustained cap-rate reset in which funds from operations and the multiple compress together.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($18.95) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The structural case carries about a fifth of the weight and is mechanically simple. Life-science supply additions keep laboratory vacancy elevated for years, so renewal spreads turn negative just as higher-for-longer rates push cap rates out. Same-store net operating income declines, occupancy slips, and funds from operations per share erode while the applied multiple compresses; both legs of the valuation fail at once, which is why the outcome is not a modest de-rating. With net debt of ~$9.5B, refinancing at higher coupons absorbs a growing share of net operating income, and the distribution leaves little retained cash to deleverage, so a distribution reset becomes plausible rather than remote. The implied structural target sits below the 52-week low, which means the market has not yet priced this path, and nothing in current prints refutes it.

Key Debate

P/E Multiple explains 83% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

What the Market Is Pricing In

Variant perception: the house view is below-consensus, and the thesis is primarily FCF-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Rate Shock / Oversupply / Secular Decline' downside ($10.50) to a 'Bull — Cap-Rate Compression / Re-Rate' bull case ($32.30); the probability-weighted blend (PWEV $20.70) is +9% versus spot.

SBC charge: scenario targets are gross per-share prices; the PWEV is reduced by one year of stock-based-compensation dilution (0.1% of shares, on SBC ≈ 1% of revenue), trimming the gross PWEV of $20.72 to $20.70 (-0.1%). SBC is charged once, as dilution — never also deducted from FCF.

Scenario rationale — the driver path behind every target:

• Structural — Rate Shock / Oversupply / Secular Decline (20%, $10.50). Structural impairment — rate shock / oversupply / secular decline: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Recession / Occupancy & SS-NOI Decline (17%, $17.10). Cyclical downturn — same-store NOI + occupancy + FFO growth + cap rates / interest rates + dividend weakens for 1–2 years before normalising.
• Base — FFO Growth + Stable Cap Rates (35%, $21.80). Mid-cycle — normalised same-store NOI + occupancy + FFO growth + cap rates / interest rates + dividend; disciplined capital allocation; steady returns.
• Growth — Same-Store NOI + External Growth (20%, $27.50). Upside — NOI growth + cap-rate compression lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Cap-Rate Compression / Re-Rate (8%, $32.30). Upside tail — sustained tight conditions or a structural re-rate on NOI growth + cap-rate compression.

Valuation Triangulation

Two weighted anchors — a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the scenario PWEV, any DCF's exit-multiple terminal and any peer re-rate key off a market multiple, so they are not independent; only a DCF's explicit-period cash flows are multiple-free, and its terminal usually carries most of its value. The discipline is to read the spread, not to treat two numbers as two independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name DCF, sum-of-parts, peer P/E re-rate are not computed, so 60% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

FFO, P/FFO & Distributions

For a REIT, GAAP EPS is meaningless — depreciation is a massive non-cash charge, so REITs are valued on Funds From Operations (FFO ≈ net income + real-estate D&A) and P/FFO, not P/E. Every 'earnings' and 'multiple' figure in this report is therefore on an FFO basis.

The valuation runs on FFO × P/FFO (the standard REIT frame); the cash-flow DCF is omitted (a REIT's development/maintenance capex is funded against the asset base, not free cash). The dividend yield (5.8%) is the income anchor; cap-rate / interest-rate moves and same-store NOI drive the scenarios.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $18.75 and 49% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (83% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $29.50; the peer-median forward P/E is 10.8x, but the engine carries no P/E-implied price for this name (valued on FFO per share). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 52% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Peer Quality & Weighting

Quality-weighted forward P/E: 12.9× (simple median 10.8×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $15.70–$22.95, centre $19.00 (+0% vs spot); spot sits at the 45th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk = (triangulated FV ÷ price − 1) ÷ (1 − 'Structural — Rate Shock / Oversupply / Secular Decline' target ÷ price). 'Structural — Rate Shock / Oversupply / Secular Decline' ($10.50, probability 20%) is the lowest-target scenario in the tree, taken gross of SBC dilution. Bull case (Bull — Cap-Rate Compression / Re-Rate): $32.30.

Company Overview & Business Model

Healthpeak Properties Inc — REAL ESTATE · REIT - HEALTHCARE FACILITIES. Business description withheld — the description on file does not name this company; reported for correction rather than published under the wrong name.

How it makes money.

† Model margin = gross margin − the opex ratio calibrated so the Monte Carlo median EPS meets the EPS target; it is not a reported operating margin.

Reported operating margin (GAAP): 19.3% for the fiscal year ended 2025-12-31; 17.6% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).

Edge. Narrow moat. Authored moat rationale withheld pending re-authoring.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

For comparison, the company's reported GAAP operating margin was 19.3% for the fiscal year ended 2025-12-31; 17.6% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 1240% — cash-backed.

Competitive Moat

Moat sources:

• On-campus / health-system-affiliated medical outpatient buildings with high tenant retention
• Purpose-built life-science lab assets in innovation clusters (specialised, hard to relocate)
• Long-lease credit tenancy tied to hospital systems
• Scale and cost of capital vs sub-scale healthcare landlords

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.42 vs analyst floor +0.00 → delta +0.42 (n=11 mgmt / 6 Q&A; 51st pctile across the S&P book, z +0.0).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 215 articles): avg ticker sentiment +0.16 (bullish 7% / bearish 0%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-11-02 (~21d) — Quarterly earnings — est. EPS $0.43 (AV EARNINGS_CALENDAR)
• 2027-02-10 (~121d) — FY2027 FFO and same-store NOI guidance (authored)

Forecast Track Record

• EPS surprise: beat 50% of the last 8 quarters; average surprise +7.2%.

Catalyst Timeline

8 catalysts in the next 90 days (of 16 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 0 bearish / 1 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is what the model's own rules read on this name; it does not modify the published research rating, and it is not personal financial advice.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Same-store cash NOI growth (blended portfolio) < 1.5% (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Lab segment occupancy < 93% (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• FY FFO-as-adjusted per share guidance < $1.80 (single event). (rationale withheld pending re-authoring — frozen figure or verdict)
• Net debt / adjusted EBITDA > 6.0x (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
• Common dividend declared per share < $0.305 quarterly (single event). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $18.95; 52-week range $15.70–$22.95; engine rating HOLD; house target $20.66 (+9%). (source: Alpha Vantage 2026-10-12, 13 October 2026)
• INFERENCE: Triangulated FV $19.97 (+5% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

49.9/100 (confidence band 37.0–62.9), 18th percentile of 928 covered names (as of 2026-10-12). Weighted composite under config ros-1.21.0 — every component and its inputs below.

Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.

Score history: 47.8 → 48.3 → 49.8 → 50.5 → 50.4 → 47.9 → 50.3 → 50.1.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $20.72.

Factor Exposures

Cross-sectional percentiles over 928 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.32, vs QQQ +0.21 (trailing ~1y daily returns).

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies +9% vs spot
• Monte Carlo median implies -1% vs spot
• Bear case (Structural — Rate Shock / Oversupply / Secular Decline) downside is -45% vs spot
• Net: reward/risk of 0.1× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Assumption Register

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

No DCF anchor is meaningful for this asset; the blend leans 62% on probability-weighted scenarios and 37% on the Monte Carlo median — the scenario probabilities are the load-bearing inputs.